Nektar Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell NKTR and other ETFs, options, and stocks.About NKTR
Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit.
CEOHoward W. Robin
CEOHoward W. Robin
Employees61
Employees61
HeadquartersSan Francisco, California
HeadquartersSan Francisco, California
Founded1990
Founded1990
Employees61
Employees61
NKTR Key Statistics
Market cap1.08B
Market cap1.08B
Price-Earnings ratio-6.53
Price-Earnings ratio-6.53
Dividend yield—
Dividend yield—
Average volume742.94K
Average volume742.94K
High today$59.90
High today$59.90
Low today$55.16
Low today$55.16
Open price$57.99
Open price$57.99
Volume942.70K
Volume942.70K
52 Week high$62.95
52 Week high$62.95
52 Week low$6.48
52 Week low$6.48
NKTR News
Simply Wall St 2d
How Investors Are Reacting To Nektar Therapeutics Securing FDA Fast Track For Eczema Drug CandidateIn recent news, Nektar Therapeutics announced that its lead candidate, rezpegaldesleukin, received Fast Track Designation from the FDA following strong performa...
Nasdaq 3d
This Stock Is Up By 285% This Year But Could Still Jump By 53%, According to Wall StreetKey Points Nektar Therapeutics' leading candidate is performing well so far in phase 2 studies. This medicine could disrupt the large and competitive eczema t...
Analyst ratings
75%
of 8 ratingsBuy
75%
Hold
12.5%
Sell
12.5%
People also own
Based on the portfolios of people who own NKTR. This list is generated using Robinhood data, and it’s not a recommendation.